Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000326

Azelastine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one hydrochloride, Astelin, Optivar

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C22H24ClN3O · HCl
Numéro CAS:
79307-93-0
Poids moléculaire :
418.36
Numéro MDL:
MFCD00242783
Code UNSPSC :
41116107
ID de substance PubChem :
329830908
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

azelastine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Cl.CN1CCCC(CC1)N2N=C(Cc3ccc(Cl)cc3)c4ccccc4C2=O

InChI

1S/C22H24ClN3O.ClH/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16;/h2-3,6-11,18H,4-5,12-15H2,1H3;1H

Clé InChI

YEJAJYAHJQIWNU-UHFFFAOYSA-N

Informations sur le gène

human ... HRH1(3269)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Azelastine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

H1 histamine receptor antagonist; NF-kB activator.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000327

Azelastine impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000328

Azelastine impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000329

Azelastine impurity E, European Pharmacopoeia (EP) Reference Standard

1046158

Azelastine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1046191

Azelastine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1046202

Azelastine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1046170

Azelastine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1046213

Azelastine Related Compound F, United States Pharmacopeia (USP) Reference Standard

PHR2842

Azelastine Related Compound D

PHR2843

Azelastine Related Compound E, certified reference material, pharmaceutical secondary standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Conseils de prudence

P301 + P312 + P330

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Warner Carr et al.
The Journal of allergy and clinical immunology, 129(5), 1282-1289 (2012-03-16)
Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients using multiple therapies and achieving limited symptom control. More effective therapies must be developed and tested in well-controlled, randomized, prospective studies with a direct comparison to current standards.
Panayiotis A Procopiou et al.
Bioorganic & medicinal chemistry, 20(20), 6097-6108 (2012-09-19)
5-Aza, 6-aza, 7-aza and 8-aza-phthalazinone, and 5,8-diazaphthalazinone templates were synthesised by stereoselective routes starting from the appropriate pyridine/pyrazine dicarboxylic acids by activation with CDI, reaction with 4-chlorophenyl acetate ester enolate to give a β-ketoester, which was hydrolysed, and decarboxylated. The
William C Howland et al.
International forum of allergy & rhinology, 1(4), 275-279 (2012-01-31)
A previous study with azelastine nasal spray in patients with seasonal allergic rhinitis (SAR) demonstrated that increasing the azelastine concentration from 0.1% to 0.15% allowed for once-daily dosing without increasing the incidence of adverse effects. This study evaluated the efficacy
L-L Fu et al.
Cell proliferation, 47(4), 326-335 (2014-06-27)
The aim of this study was to explore sodium taurocholate co-transporting polypeptide (NTCP) exerting its function with hepatitis B virus (HBV) and its targeted candidate compounds, in HBV therapy. Identification of NTCP as a novel HBV target for screening candidate
Tsugunobu Andoh et al.
Journal of pharmacological sciences, 114(3), 292-297 (2010-10-16)
Recently, we showed that a methanol extract of Ganoderma lucidum inhibits scratching, an itch-related response, induced by intradermal injections of some pruritogens in mice. The present study investigated whether G. lucidum extract would inhibit allergic itch. In mice sensitized with
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique